HVA
NFEC-2024-576
Phase 3 small_molecule active
Quick answer
HVA for Newly Diagnosed Acute Myeloid Leukemia With High Risk is a Phase 3 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Newly Diagnosed Acute Myeloid Leukemia With High Risk
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active